Global Genome Editing Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

List of Tables

The global demand for Genome Editing Market is presumed to reach the market size of nearly USD 28.98 BN by 2030 from USD 7.59 BN in 2022 with a CAGR of 18.23% under the study period 2023 - 2030.

Genome editing is a precise and targeted technique used to modify or alter the DNA sequence within an organism's genome. It involves making intentional changes to the genetic material, enabling scientists to add, remove, or modify specific DNA sequences within an organism's genome.

MARKET DYNAMICS:

Advancements in CRISPR and other editing technologies offer more precise and accessible methods for genetic manipulation, fostering market expansion. Genome editing plays a pivotal role in biomedical research, aiding in understanding disease mechanisms, drug discovery, and potential therapies, driving its demand in the biopharmaceutical sector. The increasing prevalence of genetic disorders fuels the development of therapies targeting genetic mutations, further propelling the market. In agriculture and livestock, this editing is used to enhance traits, improve yields, and develop disease-resistant varieties, contributing to its growth in agricultural biotechnology. Supportive regulatory frameworks, increased R&D investments, and the therapeutic potential of genome editing in treating various conditions fuel market expansion. Collaborations among institutions and industry players drive innovation, leading to novel applications and therapies. Despite challenges like off-target effects and ethical concerns, the genome editing market continues to expand, driven by technological advancements and its potential to revolutionize biomedical research, agriculture, and therapeutic interventions across diverse sectors.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of genome editing. The growth and trends of genome editing industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the genome editing market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Technology

Meganucleases
CRISPR)/Cas9
TALENs/MegaTALs
ZFN
Others

By Delivery Method

Ex-Vivo
In-Vivo

By Mode

Contract
In-House

By End-Use

Biotechnology & Pharmaceutical Companies
Academic & Government Research Institutes
Contract Research Organizations

By Application

Genetic Engineering (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Others)
Clinical Applications (Diagnostics, Therapy Development)

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Genome Editing market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Genome Editing market include Merck KGaA, Cibus, Recombinetics, Inc., Sangamo, Editas Medicine, Precision Biosciences, CRISPR Therapeutics, Intellia Therapeutics, Inc., Caribou Biosciences, Inc., Cellectis, AstraZeneca, Takara Bio USA, Horizon Discovery Group plc, Integrated DNA Technologies, Inc., Egenesis Inc., GenScript, New England Biolabs, OriGene Technologies, Inc., Lonza, Thermo Fisher Scientific, Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112112859

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . GENOME EDITING - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Technology
- 3.7.2 Market Attractiveness Analysis By Delivery Method
- 3.7.3 Market Attractiveness Analysis By Mode
- 3.7.4 Market Attractiveness Analysis By End-use
- 3.7.5 Market Attractiveness Analysis By Application
- 3.7.6 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL GENOME EDITING MARKET ANALYSIS BY TECHNOLOGY

5.1 Overview by Technology
5.2 Historical and Forecast Data
5.3 Analysis by Technology
5.4 Meganucleases Historic and Forecast Sales by Regions
5.5 (CRISPR)/Cas9 Historic and Forecast Sales by Regions
5.6 TALENs/MegaTALs Historic and Forecast Sales by Regions
5.7 ZFN Historic and Forecast Sales by Regions
5.8 Others Historic and Forecast Sales by Regions

6 . GLOBAL GENOME EDITING MARKET ANALYSIS BY DELIVERY METHOD

6.1 Overview by Delivery Method
6.2 Historical and Forecast Data
6.3 Analysis by Delivery Method
6.4 Ex-vivo Historic and Forecast Sales by Regions
6.5 In-vivo Historic and Forecast Sales by Regions

7 . GLOBAL GENOME EDITING MARKET ANALYSIS BY MODE

7.1 Overview by Mode
7.2 Historical and Forecast Data
7.3 Analysis by Mode
7.4 Contract Historic and Forecast Sales by Regions
7.5 In-house Historic and Forecast Sales by Regions

8 . GLOBAL GENOME EDITING MARKET ANALYSIS BY END-USE

8.1 Overview by End-use
8.2 Historical and Forecast Data
8.3 Analysis by End-use
8.4 Biotechnology & Pharmaceutical Companies Historic and Forecast Sales by Regions
8.5 Academic & Government Research Institutes Historic and Forecast Sales by Regions
8.6 Contract Research Organizations Historic and Forecast Sales by Regions

9 . GLOBAL GENOME EDITING MARKET ANALYSIS BY APPLICATION

9.1 Overview by Application
9.2 Historical and Forecast Data
9.3 Analysis by Application
9.4 Genetic Engineering (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Others) Historic and Forecast Sales by Regions
9.5 Clinical Applications (Diagnostics, Therapy Development) Historic and Forecast Sales by Regions

10 . GLOBAL GENOME EDITING MARKET ANALYSIS BY GEOGRAPHY

10.1. Regional Outlook
10.2. Introduction
10.3. North America Sales Analysis
- 10.3.1. Overview, Historic and Forecast Data Sales Analysis
- 10.3.2. North America By Segment Sales Analysis
- 10.3.3. North America By Country Sales Analysis
- 10.3.4. United State Sales Analysis
- 10.3.5. Canada Sales Analysis
- 10.3.6. Mexico Sales Analysis
10.4. Europe Sales Analysis
- 10.4.1. Overview, Historic and Forecast Data Sales Analysis
- 10.4.2. Europe by Segment Sales Analysis
- 10.4.3. Europe by Country Sales Analysis
- 10.4.4. United Kingdom Sales Analysis
- 10.4.5. France Sales Analysis
- 10.4.6. Germany Sales Analysis
- 10.4.7. Italy Sales Analysis
- 10.4.8. Russia Sales Analysis
- 10.4.9. Rest Of Europe Sales Analysis
10.5. Asia Pacific Sales Analysis
- 10.5.1. Overview, Historic and Forecast Data Sales Analysis
- 10.5.2. Asia Pacific by Segment Sales Analysis
- 10.5.3. Asia Pacific by Country Sales Analysis
- 10.5.4. China Sales Analysis
- 10.5.5. India Sales Analysis
- 10.5.6. Japan Sales Analysis
- 10.5.7. South Korea Sales Analysis
- 10.5.8. Australia Sales Analysis
- 10.5.9. South East Asia Sales Analysis
- 10.5.10. Rest Of Asia Pacific Sales Analysis
10.6. Latin America Sales Analysis
- 10.6.1. Overview, Historic and Forecast Data Sales Analysis
- 10.6.2. Latin America by Segment Sales Analysis
- 10.6.3. Latin America by Country Sales Analysis
- 10.6.4. Brazil Sales Analysis
- 10.6.5. Argentina Sales Analysis
- 10.6.6. Peru Sales Analysis
- 10.6.7. Chile Sales Analysis
- 10.6.8. Rest of Latin America Sales Analysis
10.7. Middle East & Africa Sales Analysis
- 10.7.1. Overview, Historic and Forecast Data Sales Analysis
- 10.7.2. Middle East & Africa by Segment Sales Analysis
- 10.7.3. Middle East & Africa by Country Sales Analysis
- 10.7.4. Saudi Arabia Sales Analysis
- 10.7.5. UAE Sales Analysis
- 10.7.6. Israel Sales Analysis
- 10.7.7. South Africa Sales Analysis
- 10.7.8. Rest Of Middle East And Africa Sales Analysis

11 . COMPETITIVE LANDSCAPE OF THE GENOME EDITING COMPANIES

11.1. Genome Editing Market Competition
11.2. Partnership/Collaboration/Agreement
11.3. Merger And Acquisitions
11.4. New Product Launch
11.5. Other Developments

12 . COMPANY PROFILES OF GENOME EDITING INDUSTRY

12.1. Company Share Analysis
12.2. Market Concentration Rate
12.3. Merck KGaA
- 12.3.1. Company Overview
- 12.3.2. Company Revenue
- 12.3.3. Products
- 12.3.4. Recent Developments
12.4. Cibus
- 12.4.1. Company Overview
- 12.4.2. Company Revenue
- 12.4.3. Products
- 12.4.4. Recent Developments
12.5. Recombinetics Inc.
- 12.5.1. Company Overview
- 12.5.2. Company Revenue
- 12.5.3. Products
- 12.5.4. Recent Developments
12.6. Sangamo
- 12.6.1. Company Overview
- 12.6.2. Company Revenue
- 12.6.3. Products
- 12.6.4. Recent Developments
12.7. Editas Medicine
- 12.7.1. Company Overview
- 12.7.2. Company Revenue
- 12.7.3. Products
- 12.7.4. Recent Developments
12.8. Precision Biosciences
- 12.8.1. Company Overview
- 12.8.2. Company Revenue
- 12.8.3. Products
- 12.8.4. Recent Developments
12.9. CRISPR Therapeutics
- 12.9.1. Company Overview
- 12.9.2. Company Revenue
- 12.9.3. Products
- 12.9.4. Recent Developments
12.10. Intellia Therapeutics Inc.
- 12.10.1. Company Overview
- 12.10.2. Company Revenue
- 12.10.3. Products
- 12.10.4. Recent Developments
12.11. Caribou Biosciences Inc.
- 12.11.1. Company Overview
- 12.11.2. Company Revenue
- 12.11.3. Products
- 12.11.4. Recent Developments
12.12. Cellectis
- 12.12.1. Company Overview
- 12.12.2. Company Revenue
- 12.12.3. Products
- 12.12.4. Recent Developments
12.13. AstraZeneca
- 12.13.1. Company Overview
- 12.13.2. Company Revenue
- 12.13.3. Products
- 12.13.4. Recent Developments
12.14. Takara Bio USA
- 12.14.1. Company Overview
- 12.14.2. Company Revenue
- 12.14.3. Products
- 12.14.4. Recent Developments
12.15. Horizon Discovery Group plc
- 12.15.1. Company Overview
- 12.15.2. Company Revenue
- 12.15.3. Products
- 12.15.4. Recent Developments
12.16. Integrated DNA Technologies Inc.
- 12.16.1. Company Overview
- 12.16.2. Company Revenue
- 12.16.3. Products
- 12.16.4. Recent Developments
12.17. Egenesis Inc.
- 12.17.1. Company Overview
- 12.17.2. Company Revenue
- 12.17.3. Products
- 12.17.4. Recent Developments
12.18. GenScript
- 12.18.1. Company Overview
- 12.18.2. Company Revenue
- 12.18.3. Products
- 12.18.4. Recent Developments
12.19. New England Biolabs
- 12.19.1. Company Overview
- 12.19.2. Company Revenue
- 12.19.3. Products
- 12.19.4. Recent Developments
12.20. OriGene Technologies Inc.
- 12.20.1. Company Overview
- 12.20.2. Company Revenue
- 12.20.3. Products
- 12.20.4. Recent Developments
12.21. Lonza
- 12.21.1. Company Overview
- 12.21.2. Company Revenue
- 12.21.3. Products
- 12.21.4. Recent Developments
12.22. Thermo Fisher Scientific Inc.
- 12.22.1. Company Overview
- 12.22.2. Company Revenue
- 12.22.3. Products
- 12.22.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies